NCT02721459 2026-03-02XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV MelanomaH. Lee Moffitt Cancer Center and Research InstitutePhase 1 Active not recruiting26 enrolled